NCT04800263 is a Phase 1 clinical trial of SHR-1905 in Asthma, sponsored by Atridia Pty Ltd..

Who is sponsoring NCT04800263?

NCT04800263 is sponsored by Atridia Pty Ltd..

What drugs are being tested in NCT04800263?

Interventions in NCT04800263: SHR-1905, Placebo.

Is NCT04800263 still recruiting?

NCT04800263 is currently completed. Last updated 10 May 2023.

Last reviewed 2023-05-10 · How we verify

NCT04800263

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Trial of SHR-1905 in Healthy Subjects

Completed Phase 1 Last updated 10 May 2023

What this trial tests

Phase 1 trial testing SHR-1905 in Asthma in 50 participants. Completed in 12 November 2022.

Timeline

27 July 2021

Primary endpoint
12 November 2022

12 November 2022

Quick facts

Lead sponsor	Atridia Pty Ltd.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	50
Start date	27 July 2021
Primary completion	12 November 2022
Estimated completion	12 November 2022
Sites	1 location across Australia

Drugs / interventions tested

SHR-1905
Placebo

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Atridia Pty Ltd. — full company profile →

Who can join

Adults 18 to 55, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blind, placebo-controlled, single dose escalation phase 1 study. The objective of this study is to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of subcutaneous administered SHR-1905 in healthy subjects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

A phase 1, randomized, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and immunogenicity of SHR-1905, a long-acting anti-thymic stromal lymphopoietin antibody, in healthy subjects.
Fei Y, Li N, Qian W, Fan Y, et al · · 2024 · cited 4× · PMID 39076593 · DOI 10.3389/fphar.2024.1400696
Potential of alarmin-targeted bispecific and combination therapies in airway disease.
Komori HK, Ortega H. · · 2025 · PMID 41409758 · DOI 10.3389/falgy.2025.1700060

Verify or expand the search:

Other trials of SHR-1905

Trials testing the same drug.

NCT05593250 — A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma · Phase 2 · active not recruiting

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Atridia Pty Ltd. trials

Trials by the same sponsor.

NCT07358377 — To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negati · Phase 1 · not yet recruiting
NCT07390747 — A Trial of SHR-2173 in Healthy Volunteers · Phase 1 · recruiting
NCT07238647 — A Trial of HRS-5817 in Obese Participants · EARLY_PHASE1 · recruiting
NCT07078695 — A Trial of SHR-1139 in Healthy Volunteers · Phase 1 · active not recruiting
NCT07033455 — A Trial of HRS-1893 in Healthy Volunteers · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04800263 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Atridia Pty Ltd.
Last refreshed: 10 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04800263.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing